Diagnosis and treatment of primary aldosteronism
Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigatio...
Gespeichert in:
Veröffentlicht in: | The lancet. Diabetes & endocrinology 2021-12, Vol.9 (12), p.876-892 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 892 |
---|---|
container_issue | 12 |
container_start_page | 876 |
container_title | The lancet. Diabetes & endocrinology |
container_volume | 9 |
creator | Reincke, Martin Bancos, Irina Mulatero, Paolo Scholl, Ute I Stowasser, Michael Williams, Tracy Ann |
description | Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism. |
doi_str_mv | 10.1016/S2213-8587(21)00210-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_pubmed_primary_34798068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213858721002102</els_id><sourcerecordid>2600286915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</originalsourceid><addsrcrecordid>eNqFkE9PwzAMxSMEYtPYRwD1OA4FJ23S5ITQ-CtN4gCco7RxUVDbjKRD4tvTbWVXTras92y_HyHnFK4oUHH9yhjNUsllsWD0EoBRSNkRmY5jxY8PvSwmZB7jJwBQ4JmQcEomWV4oCUJOCdw589H56GJiOpv0AU3fYtcnvk7WwbUm_CSmsT72GHznYntGTmrTRJyPdUbeH-7flk_p6uXxeXm7SqtcZn1aMFDS1hKFVQplLfMyL5Bntam5ZCWvqTJY5oqCEFAgitIayoHlUEAuIM9mZLHfuw7-a4Ox162LFTaN6dBvomZiiC2FonyQ8r20Cj7GgLUeP9cU9JaX3vHSWxiaUb3jpdnguxhPbMoW7cH1R2cQ3OwFOAT9dhh0rBx2FVoXsOq19e6fE7_NRXhl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2600286915</pqid></control><display><type>article</type><title>Diagnosis and treatment of primary aldosteronism</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</creator><creatorcontrib>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</creatorcontrib><description>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</description><identifier>ISSN: 2213-8587</identifier><identifier>EISSN: 2213-8595</identifier><identifier>DOI: 10.1016/S2213-8587(21)00210-2</identifier><identifier>PMID: 34798068</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenoma - complications ; Adrenalectomy ; Adrenocortical Adenoma - complications ; Aldosterone ; Humans ; Hyperaldosteronism - diagnosis ; Hyperaldosteronism - genetics ; Hyperaldosteronism - therapy ; Hypertension - complications ; Quality of Life</subject><ispartof>The lancet. Diabetes & endocrinology, 2021-12, Vol.9 (12), p.876-892</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</citedby><cites>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34798068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Mulatero, Paolo</creatorcontrib><creatorcontrib>Scholl, Ute I</creatorcontrib><creatorcontrib>Stowasser, Michael</creatorcontrib><creatorcontrib>Williams, Tracy Ann</creatorcontrib><title>Diagnosis and treatment of primary aldosteronism</title><title>The lancet. Diabetes & endocrinology</title><addtitle>Lancet Diabetes Endocrinol</addtitle><description>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</description><subject>Adenoma - complications</subject><subject>Adrenalectomy</subject><subject>Adrenocortical Adenoma - complications</subject><subject>Aldosterone</subject><subject>Humans</subject><subject>Hyperaldosteronism - diagnosis</subject><subject>Hyperaldosteronism - genetics</subject><subject>Hyperaldosteronism - therapy</subject><subject>Hypertension - complications</subject><subject>Quality of Life</subject><issn>2213-8587</issn><issn>2213-8595</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwzAMxSMEYtPYRwD1OA4FJ23S5ITQ-CtN4gCco7RxUVDbjKRD4tvTbWVXTras92y_HyHnFK4oUHH9yhjNUsllsWD0EoBRSNkRmY5jxY8PvSwmZB7jJwBQ4JmQcEomWV4oCUJOCdw589H56GJiOpv0AU3fYtcnvk7WwbUm_CSmsT72GHznYntGTmrTRJyPdUbeH-7flk_p6uXxeXm7SqtcZn1aMFDS1hKFVQplLfMyL5Bntam5ZCWvqTJY5oqCEFAgitIayoHlUEAuIM9mZLHfuw7-a4Ox162LFTaN6dBvomZiiC2FonyQ8r20Cj7GgLUeP9cU9JaX3vHSWxiaUb3jpdnguxhPbMoW7cH1R2cQ3OwFOAT9dhh0rBx2FVoXsOq19e6fE7_NRXhl</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Reincke, Martin</creator><creator>Bancos, Irina</creator><creator>Mulatero, Paolo</creator><creator>Scholl, Ute I</creator><creator>Stowasser, Michael</creator><creator>Williams, Tracy Ann</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Diagnosis and treatment of primary aldosteronism</title><author>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoma - complications</topic><topic>Adrenalectomy</topic><topic>Adrenocortical Adenoma - complications</topic><topic>Aldosterone</topic><topic>Humans</topic><topic>Hyperaldosteronism - diagnosis</topic><topic>Hyperaldosteronism - genetics</topic><topic>Hyperaldosteronism - therapy</topic><topic>Hypertension - complications</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Mulatero, Paolo</creatorcontrib><creatorcontrib>Scholl, Ute I</creatorcontrib><creatorcontrib>Stowasser, Michael</creatorcontrib><creatorcontrib>Williams, Tracy Ann</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet. Diabetes & endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reincke, Martin</au><au>Bancos, Irina</au><au>Mulatero, Paolo</au><au>Scholl, Ute I</au><au>Stowasser, Michael</au><au>Williams, Tracy Ann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and treatment of primary aldosteronism</atitle><jtitle>The lancet. Diabetes & endocrinology</jtitle><addtitle>Lancet Diabetes Endocrinol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>9</volume><issue>12</issue><spage>876</spage><epage>892</epage><pages>876-892</pages><issn>2213-8587</issn><eissn>2213-8595</eissn><abstract>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34798068</pmid><doi>10.1016/S2213-8587(21)00210-2</doi><tpages>17</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2213-8587 |
ispartof | The lancet. Diabetes & endocrinology, 2021-12, Vol.9 (12), p.876-892 |
issn | 2213-8587 2213-8595 |
language | eng |
recordid | cdi_pubmed_primary_34798068 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Adenoma - complications Adrenalectomy Adrenocortical Adenoma - complications Aldosterone Humans Hyperaldosteronism - diagnosis Hyperaldosteronism - genetics Hyperaldosteronism - therapy Hypertension - complications Quality of Life |
title | Diagnosis and treatment of primary aldosteronism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A49%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20treatment%20of%20primary%20aldosteronism&rft.jtitle=The%20lancet.%20Diabetes%20&%20endocrinology&rft.au=Reincke,%20Martin&rft.date=2021-12&rft.volume=9&rft.issue=12&rft.spage=876&rft.epage=892&rft.pages=876-892&rft.issn=2213-8587&rft.eissn=2213-8595&rft_id=info:doi/10.1016/S2213-8587(21)00210-2&rft_dat=%3Cproquest_cross%3E2600286915%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2600286915&rft_id=info:pmid/34798068&rft_els_id=S2213858721002102&rfr_iscdi=true |